| Literature DB >> 21572699 |
Payam Tabarsi1, Ahmadreza Moradi, Majid Marjani, Parvaneh Baghaei, Seyed Mohammadreza Hashemian Hashemian, Seyed Alireza Nadji, Atefeh Fakharian, Davood Mansouri, Mohammadreza Masjedi, Aliakbar Velayati.
Abstract
BACKGROUND: In preparation for pandemic HINI or H1N1 influenza (H1N1) it is necessary to identify factors associated with mortality of patients with HINI and hospital admissions to intensive care unit (ICU) of patients diagnosed in 2009 with HINI.Entities:
Keywords: Hospital mortality; influenza a virus H1N1 subtype; intensive care units; risk factors
Year: 2011 PMID: 21572699 PMCID: PMC3081563 DOI: 10.4103/1817-1737.78429
Source DB: PubMed Journal: Ann Thorac Med ISSN: 1998-3557 Impact factor: 2.219
Baseline characteristics of hospitalized patients with laboratory-confirmed 2009 pandemic (H1N1) influenza
| Characteristic | Total ( | ICU ( | Hospital (other than ICU) ( | |
|---|---|---|---|---|
| Demographic factors | ||||
| Age in years | ||||
| Mean | 35.91 ± 1.3 | 36.9 ± 12.9 | 35.15 ± 13.17 | 0.655 |
| Range | 15-66 | 21-66 | 15-61 | |
| Female gender, % | 43.5 | 50 | 38.4 | 0.31 |
| Smoker, % | 15.2 | 20 | 11.5 | 0.35 |
| Opium use, % | 17.4 | 35 | 3.8 | 0.01 |
| IVDU, % | 4.3 | 10 | 0 | 0.18 |
| Alcohol use, % | 0 | – | – | |
| Close contact with H1N1 cases, % | 10.9 | 5 | 15.4 | 0.36 |
| Mean time interval between beginning of symptoms to admission, days | 5.6 ± 3.8 | 6.4 ± 3.5 | 5 ± 3.9 | |
| Reported symptoms, % | ||||
| Cough | 97.8 | 95 | 100 | 0.43 |
| Fever | 91.3 | 90 | 96.2 | 0.57 |
| Chills | 80.4 | 85 | 80.8 | 0.99 |
| Sputum | 78.3 | 95 | 65.4 | 0.02 |
| Dyspnea | 78.3 | 90 | 69 | 0.08 |
| Myalgia | 69.6 | 70 | 69.2 | 0.95 |
| Chest pain | 39.1 | 55 | 26.9 | 0.05 |
| Sweat | 37 | 50 | 26.9 | 0.10 |
| Diarrhea | 34.8 | 35 | 34.6 | 0.97 |
| Hemoptysis | 30.4 | 55 | 11.5 | 0.03 |
| Vomiting | 28.3 | 20 | 34.6 | 0.33 |
| Headache | 15.2 | 5 | 23.1 | 0.11 |
| Altered mental status | 13 | 30 | 0 | 0.004 |
| Abdominal pain | 8.7 | 5 | 11.5 | 0.62 |
| Loss of consciousness | 8.7 | 20 | 0 | 0.03 |
| Sore throat | 4.3 | 0 | 7.7 | 0.49 |
| Coinfection with seasonal influenza A | 32.6 | 30 | 34.6 | 0.49 |
| Outcome, % | ||||
| Need to mechanical ventilation | 26.1 | 60 | 0 | 0.001 |
| ICU stay, day | N/A | 14.63 ± 13.11 | N/A | N/A |
| Ventilation day | N/A | 6.26 ± 11.48 | N/A | N/A |
| Death | 15.2 | 30 | 3.8 | 0.03 |
P values are for the comparison of patients admitted to ICU and regular wards; missing data were excluded.
The P value was calculated with the use of the t-test.
The P value was calculated with the use of a two-sided χ2-tsest.
The Pvalue was calculated with the use of a two-sided Fisher’s exact test because of the small number of patients (in one or both groups)
Patients could have more than one symptom; ICU: Intensive care unit, IVDU: Intra venous drug user
Co-existing conditions, para clinical data, and treatment regimen of hospitalized patients with laboratoryconfirmed 2009 pandemic (H1N1) influenza
| Characteristic | Total ( | ICU ( | Hospital (other than ICU) ( | |
|---|---|---|---|---|
| Lab data, % | ||||
| Leukocytosis | 25.6 | 25 | 26.1 | 0.9† |
| Leukocytopenia | 11.6 | 20 | 4.3 | 0.1‡ |
| Thrombocytopenia | 41.9 | 55 | 30.4 | 0.1† |
| Anemia | 34.9 | 35 | 34.8 | 0.9‡ |
| Elevated LFT | 65.2 | 85 | 54.2 | 0.05‡ |
| CPK | 440 ± 567 | 639 ± 696 | 259 ± 342 | 0.02║ |
| LDH | 825 ± 609 | 115±727 | 550 ± 286 | 0.001║ |
| ESR | 45.9 ± 35.2 | 47.5 ± 36.4 | 44.3 ± 35 | 0.7║ |
| O2 saturation | 79.3 ± 12.9 | 70 ± 12.2 | 87.3 ± 6.8 | 0.000║ |
| Cr | 1.1 ± 1.1 | 1.4 ± 1.57 | 0.9 ± 0.2 | 0.16║ |
| Positive sputum culture for bacteria, % | 19.6 | 30 | 11.5 | 0.1‡ |
| Acinetobacter | 8.7 | |||
| Pseudomonas | 6.5 | |||
| Coagulase negative staphylococci | 4.3 | |||
| Positive blood culture, % | 10.9 | 15 | 7.7 | 0.6‡ |
| 4.3 | ||||
| Pseudomonas | 4.3 | |||
| Acinetobacter | 2.3 | |||
| Abnormal chest X-ray findings, % | 73.9 | 95 | 57.7 | 0.006‡ |
| Bilateral | 80 | 90 | 66.7 | 0.1† |
| Ground glass | 42.9 | 50 | 33.3 | |
| Patchy | 32.6 | 30 | 33.3 | |
| Consolidation | 25.7 | 20 | 33.3 | |
| Pleural effusion | 8.7 | 20 | 0 | 0.03‡ |
| Pneumothorax | 4.3 | 10 | 0 | 0.2‡ |
| Coexisting conditions, %§ | ||||
| Any | 45.7 | 45 | 46 | 0.5† |
| Asthma | 17.4 | 20 | 15 | 0.7‡ |
| Malignancy¶ | 8.7 | 5 | 11 | 0.4‡ |
| Hypertension | 8.7 | 5 | 11 | 0.4‡ |
| Transplantation‡‡ | 4.3 | 0 | 8 | 0.3‡ |
| COPD | 4.3 | 5 | 3.8 | 0.6‡ |
| HIV | 2.3 | 5 | 0 | 0.4‡ |
| Diabetes | 2.3 | 0 | 3.8 | 0.5‡ |
| Chronic renal failure | 2.3 | 5 | 0 | 0.4‡ |
| Primary immune deficiency§§ | 2.3 | 5 | 0 | 0.4‡ |
| Treatment regimen | ||||
| Oseltamivir | 100 | 100 | 100 | |
| Antibiotic | 97.8 | 100 | 97.8 | 0.5‡ |
| Ceftriaxone | 93.5 | 100 | 88.5 | 0.2‡ |
| Azithromycin | 95.7 | 100 | 92.3 | 0.4‡ |
| Vancomycin | 52.2 | 90 | 23.1 | 0.000‡ |
| Corticosteroids | 73.9 | 95 | 57.7 | 0.006‡ |
| Intravenous immunoglobulin | 4.3 | 10 | 0 | 0.1‡ |